AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|
21.7 C
New York
Friday, June 26, 2026

Tag: study

newssourceFORcompanyinformationcontent1marketreleases

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI...

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants.

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

 Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

Crazy Bulk Releases 2025 Transparency Update on Legal Steroid Alternatives

2025 Ingredient Transparency Report Highlights Clean-Label Muscle Stack Reformulations and Global Demand for Safe Performance Alternatives 
2025 Ingredient Transparency Report Highlights Clean-Label Muscle Stack Reformulations and Global Demand for Safe Performance Alternatives

G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...

[Latest] Global Bio Based Propylene Glycol Market Size/Share Worth USD 7.03 Billion by 2034 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders,...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Bio Based Propylene Glycol Market size & share revenue was valued at approximately USD 4.53 Billion in 2024 and is expected to reach USD 4.73 Billion in 2025 and is expected to reach around USD 7.03 Billion by 2034, at a CAGR of 4.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Archer Daniels Midland (ADM), BASF SE, Dow Inc., DuPont Tate & Lyle Bio Products, Huntsman International, Cargill Incorporated, Oleon NV, Ashland Global, LyondellBasell Industries, Repsol, SK Global Chemical, P&G Chemicals, Global Bio-Chem Technology Group, ExxonMobil Corporation, Stepan Company, Corbion N.V., Sinopec (China Petroleum & Chemical Corp.), Mitsubishi Chemical Corporation, Shell Chemicals & Others. 
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Bio Based Propylene Glycol Market size & share revenue was valued at approximately USD 4.53 Billion in 2024 and is expected to reach USD 4.73 Billion in 2025 and is expected to reach around USD 7.03 Billion by 2034, at a CAGR of 4.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Archer Daniels Midland (ADM), BASF SE, Dow Inc., DuPont Tate & Lyle Bio Products, Huntsman International, Cargill Incorporated, Oleon NV, Ashland Global, LyondellBasell Industries, Repsol, SK Global Chemical, P&G Chemicals, Global Bio-Chem Technology Group, ExxonMobil Corporation, Stepan Company, Corbion N.V., Sinopec (China Petroleum & Chemical Corp.), Mitsubishi Chemical Corporation, Shell Chemicals & Others.

Behr Paint Company and Google Cloud ‘Paint’ a New Future for Home Improvement with AI-Powered Color Selection

Behr now using Google Cloud AI tools for personalized color recommendations, solving a major pain point in home improvement projects SUNNYVALE, Calif., July 16, 2025...

Towpath Credit Union Transforms their Digital Banking Experience with Alkami’s Solutions

Ohio-based credit union modernizes member experience with full-scale conversion, boosting product adoption, revenue growth, and efficiency ratio PLANO, Texas, July 16, 2025 /PRNewswire/ -- Alkami...

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers